VISEN Pharmaceuticals has notified investors that its board will convene on 27 August 2026 to review and approve the interim financial results for the six months ended 30 June 2026. The meeting will also address other routine corporate matters.

The notice, dated 17 August 2026, was signed by Executive Director and Chief Executive Officer Mr. Lu An-Bang. VISEN’s current board comprises one executive director (Mr. Lu), five non-executive directors (Mr. Fu Shan, Mr. Cao Yibo, Mr. Roy Paul Khoury, Ms. Sherrie Lynn Glass and Mr. Michael J. Chang) and four independent non-executive directors (Dr. Yao Zhengbin, Mr. Chan Peng Kuan, Ms. Ni Hong and Mr. Zhang Qing).

The forthcoming board meeting will determine the company’s official H1 2026 financial disclosure timeline and content, providing the market with an update on VISEN Pharma’s operational and financial performance for the period.